Clinical Trials Browser

Approved for marketing × INDUSTRY × Carcinoma, Medullary × Clear all

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

NCT01683110 2013-01-16

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Approved for marketing

Carcinoma, Medullary